CAPRICOR THERAPEUTICS INC (CAPR) Stock Price, Quote, News and Overview
NASDAQ:CAPR - Nasdaq - US14070B3096 - Common Stock - Currency: USD
CAPR Quote, Performance and Key Statistics
CAPRICOR THERAPEUTICS INC
NASDAQ:CAPR (2/4/2025, 8:00:02 PM)
After market: 15.14 +0.07 (+0.46%)15.07
-0.11 (-0.72%)
The current stock price of CAPR is 15.07 USD. In the past month the price decreased by -3.46%. In the past year, price increased by 285.42%.
CAPR Latest News, Press Releases and Analysis
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone...
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Announced intent to file a biologics license application (BLA) for deramiocel to treat all patients with DMD-cardiomyopathy Rolling BLA submission...
Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
-Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-...
CAPR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About CAPR
Company Profile
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in San Diego, California and currently employs 101 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The firm leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
Company Info
CAPRICOR THERAPEUTICS INC
10865 Road to the Cure, Suite 150
San Diego CALIFORNIA 90211 US
CEO: Linda Marban
Employees: 102
Company Website: https://capricor.com/
Investor Relations: http://capricor.com/investors
Phone: 18587271755
CAPR FAQ
What is the stock price of CAPR?
The current stock price of CAPR is 15.07 USD.
What is the symbol for CAPRICOR THERAPEUTICS INC stock?
The exchange symbol of CAPRICOR THERAPEUTICS INC is CAPR and it is listed on the Nasdaq exchange.
On which exchange is CAPR stock listed?
CAPR stock is listed on the Nasdaq exchange.
Is CAPR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CAPR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CAPR.
Does CAPR stock pay dividends?
CAPR does not pay a dividend.
What is the Price/Earnings (PE) ratio of CAPR?
CAPR does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
What is the Short Interest ratio of CAPR stock?
The outstanding short interest for CAPR is 20.04% of its float.
CAPR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CAPR. When comparing the yearly performance of all stocks, CAPR is one of the better performing stocks in the market, outperforming 97.84% of all stocks.
CAPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CAPR. The financial health of CAPR is average, but there are quite some concerns on its profitability.
CAPR Financial Highlights
Over the last trailing twelve months CAPR reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS decreased by 8.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.7% | ||
| ROE | -49.97% | ||
| Debt/Equity | 0.05 |
CAPR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to CAPR. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -50.07% and a revenue growth -20.3% for CAPR